![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BMS, Sanofi Push Back Against Hawaii’s Plavix Litigation
BMS, Sanofi Push Back Against Hawaii’s Plavix Litigation
![GavelwithBaseBW.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/GavelwithBaseBW.gif?t=1579650370&width=430)
January 20, 2020
Bristol-Myers Squibb and Sanofi have filed a complaint against the state of Hawaii over a lawsuit that seeks massive fines against the drugmakers for failing to include a warning in labeling for their anti-blood clotting drug Plavix (clopidogrel).
According to the state, the labeling from 1998 until 2010 was false and misleading because it lacked a warning that Plavix is less effective in patients with certain genetic traits disproportionately found in Asians.
The companies face a trial in April in which the state will seek billions of dollars in penalties — $10,000 for each prescription issued in the timeframe.
Upcoming Events
-
21Oct